Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Raghuram Selvaraju

Aegis Capital Corp.

Image: Raghuram Selvaraju

Raghuram "Ram" Selvaraju's professional career started at the Geneva-based biotech firm Serono in 2000, where he discovered the first novel protein candidate developed entirely within the company. He subsequently became the youngest recipient of the company's Inventorship Award for Exceptional Innovation and Creativity. Selvaraju started in the securities industry with Rodman & Renshaw as a biotechnology equity research analyst. He was the top-ranked (#1) biotech analyst in The Wall Street Journal's "Best on the Street" survey (2006) and went on to become head of healthcare equity research at Hapoalim Securities, the New York-based broker/dealer subsidiary of Bank Hapoalim B. M., Israel's largest financial services group. While at Hapoalim, Selvaraju was regularly featured in The Wall Street Journal, Barron's, BioWorld Today, and Reuters/AP. He was also a regular guest on the Bloomberg TV program "Taking Stock," appeared with Bloomberg TV's on-air correspondents Betty Liu and Gigi Stone and was a guest on CNBC's "Street Signs with Herb Greenberg." He is currently an analyst with Aegis Capital Corp.



Recent Interviews

Ram Selvaraju: Fall in Love with These Nine Biotech Stocks (2/14/13) When it comes to unearthing dynamic micro-cap biotech investment opportunities, Ram Selvaraju is a master. Selvaraju, managing director and head of healthcare equity research at Aegis Capital Corp., has selected nine names destined to attract investors willing to take calculated risks, which he shares in this interview with The Life Sciences Report. He also explains why he expects 2013 will be another good year for the biotech industry.

The Life Sciences Report Watchlist 2013 (1/31/13) Which biotech companies will take off in 2013? To zero in on possible winners, The Life Sciences Report teamed up with Sagient Research to crunch the numbers for companies with potential catalysts on the calendar. The results were sent to experts who, based on their experience in the space, could determine which companies have the best chances for upward stock price movement. The result is the groundbreaking Life Sciences Report Watchlist 2013. In this exclusive article, you can follow the thought process that went into generating the short list, and learn more about the potential winners and what they are poised to accomplish in the next 12 months.

A Capital-Efficient Prescription for New Drugs: Raghuram "Ram" Selvaraju (11/1/12) The small biotech companies that have survived the last five years have learned to be lean, mean and efficient with shareholder capital. In this exclusive interview with The Life Sciences Report, Aegis Capital's Managing Director and Head of Equity Research Raghuram "Ram" Selvaraju discusses companies that have mitigated risk by giving new life and higher margins to products previously relegated to the dustbin of commoditized generics. He also highlights some very new and exciting developments in the realm of stem cell technologies and monoclonal antibodies that engage never-before-targeted molecules.

Recent Quotes

"CUR will soon begin dosing of NSI-566 in a phase 2 trial; this is a significant step forward." (5/20/13) Neuralstem Inc. - Raghuram Selvaraju, Aegis Capital Corp. More >

"CYTR reached an agreement with the FDA for a Special Protocol Assessment on a global pivotal phase 3 trial with aldoxorubicin." (4/24/13) CytRx Corp. - Raghuram Selvaraju, Aegis Capital Corp. More >

"Approval to begin phase 2 testing in patients with ALS is a significant step forward for CUR." (4/17/13) Neuralstem Inc. - Raghuram Selvaraju, Aegis Capital Corp. More >

"CYTR is well capitalized to fund operations through the important catalysts expected over the next next 12–15 months." (3/28/13) CytRx Corp. - Raghuram Selvaraju, Aegis Capital Corp. More >

"Animal data has indicated LPTN's ASONEP™ may have activity in renal cell carcinoma, including that which is resistant to currently marketed drugs." (3/14/13) Lpath Inc. - Raghuram Selvaraju, Aegis Capital Corp. More >

"We reiterate our Buy rating on GALE." (3/13/13) Galena Biopharma Inc. - Raghuram Selvaraju, Aegis Capital Corp. More >

"GALE is an intriguing investment opportunity at this juncture." (3/13/13) Galena Biopharma Inc. - Raghuram Selvaraju, Aegis Capital Corp. More >

"We consider LPTN's agreement with Provista a further validation of its ImmuneY2 platform." (3/7/13) Lpath Inc. - Raghuram Selvaraju, Aegis Capital Corp. More >